These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 1528304)

  • 21. Selenium (Se) cytotoxicity in drug sensitive and drug resistant murine tumour.
    Shallom J; Juvekar A; Chitnis M
    Cancer Biother; 1995; 10(3):243-8. PubMed ID: 8547963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
    Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
    Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adriamycin-induced DNA strand breaks in HeLa and in P388 leukaemia cells detected using in situ nick translation.
    Maehara Y; Emi Y; Anai H; Sakaguchi Y; Kohnoe S; Tsujitani S; Sugimachi K
    J Pathol; 1989 Dec; 159(4):323-7. PubMed ID: 2614577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha.
    McPherson JP; Deffie AM; Jones NR; Brown GA; Deuchars KL; Goldenberg GJ
    Anticancer Res; 1997; 17(6D):4243-52. PubMed ID: 9494516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
    Elstad CA; Thrall BD; Raha G; Meadows GG
    Nutr Cancer; 1996; 25(1):47-60. PubMed ID: 8837861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
    Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
    Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary screening and inhibition of macromolecular biosynthesis by benfluron metabolites in vitro.
    Miko M; Krepelka J; Mĕlka M; Vajdová D
    Neoplasma; 1989; 36(1):91-101. PubMed ID: 2704427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Murine splenocyte migration inhibition assay I. Detection of differential responses to murine leukemia P388 and its adriamycin-resistant subline P388/ADR.
    Nori M; Gothoskar BP
    Neoplasma; 1983; 30(3):287-93. PubMed ID: 6223231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity and nucleic acid binding properties of dercitin, a new acridine alkaloid isolated from a marine Dercitus species sponge.
    Burres NS; Sazesh S; Gunawardana GP; Clement JJ
    Cancer Res; 1989 Oct; 49(19):5267-74. PubMed ID: 2548717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of pyrindamycins A and B.
    Ishii S; Nagasawa M; Kariya Y; Yamamoto H; Inouye S; Kondo S
    J Antibiot (Tokyo); 1989 Nov; 42(11):1713-7. PubMed ID: 2531136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitization of P388 murine leukemia cells to epirubicin cytotoxicity by reserpine.
    Viladkar A; Chitnis M
    Cancer Biother; 1993; 8(1):77-85. PubMed ID: 7812352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
    Xu BH; Singh SV
    Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
    Ganapathi R; Grabowski D
    Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.
    Trendowski M; Mitchell JM; Corsette CM; Acquafondata C; Fondy TP
    Invest New Drugs; 2015 Apr; 33(2):290-9. PubMed ID: 25563824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
    Gutierrez PL; Wilder PJ; Biswal N
    Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential macrophage-mediated cytotoxicity to P388 leukemia cells and its drug-resistant cells examined by a new MTT assay.
    Jiao H; Soejima Y; Ohe Y; Miura K; Tamura T; Saijo N
    Leuk Res; 1992 Dec; 16(12):1175-80. PubMed ID: 1465025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS; Clement JJ
    Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bouvardin (NSC 259968) on the growth characteristics an nucleic acids and protein syntheses profiles of P388 leukemia cells.
    Chitnis MP; Alate AD; Menon RS
    Chemotherapy; 1981; 27(2):126-30. PubMed ID: 7471902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide.
    Nakashima E; Matsushita R; Negishi H; Nomura M; Harada S; Yamamoto H; Miyamoto K; Ichimura F
    J Pharm Sci; 1995 Oct; 84(10):1205-9. PubMed ID: 8801335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.